MX2015013059A - Sales, co-cristales, y polimorfos de un compuesto ansiolitico. - Google Patents
Sales, co-cristales, y polimorfos de un compuesto ansiolitico.Info
- Publication number
- MX2015013059A MX2015013059A MX2015013059A MX2015013059A MX2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- salts
- polymorphs
- compound
- pharmaceutical compositions
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000002249 anxiolytic agent Substances 0.000 title 1
- 230000000949 anxiolytic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- ZAEIHDZLLJCJFP-UHFFFAOYSA-N 6-(2,3-dihydro-1h-inden-2-ylamino)-1-ethyl-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one Chemical compound O=C1C2=CC(NC3CC4=CC=CC=C4C3)=CN=C2N(CC)C=C1C(=O)N1CCOCC1 ZAEIHDZLLJCJFP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798926P | 2013-03-15 | 2013-03-15 | |
| PCT/AU2014/000272 WO2014138812A1 (en) | 2013-03-15 | 2014-03-14 | Salts, co-crystals, and polymorphs of an anxiolytic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013059A true MX2015013059A (es) | 2016-08-05 |
Family
ID=51535621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013059A MX2015013059A (es) | 2013-03-15 | 2014-03-14 | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9745296B2 (enExample) |
| EP (1) | EP2970247A4 (enExample) |
| JP (1) | JP2016510768A (enExample) |
| CN (1) | CN105492440A (enExample) |
| AU (2) | AU2014231722B2 (enExample) |
| CA (1) | CA2905570A1 (enExample) |
| HK (1) | HK1220191A1 (enExample) |
| MX (1) | MX2015013059A (enExample) |
| WO (1) | WO2014138812A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6688434B2 (en) | 2002-02-22 | 2004-02-10 | Ecolab Inc. | Conveyor and lubricating apparatus, lubricant dispensing device, and method for applying lubricant to conveyor |
| CN105541701A (zh) * | 2015-12-11 | 2016-05-04 | 吉林大学珠海学院 | 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法 |
| TWI765688B (zh) * | 2015-12-15 | 2022-05-21 | 以色列商諾發測量儀器股份有限公司 | 用於測量圖案化結構之方法及拉曼光譜系統 |
| WO2019109150A1 (en) * | 2017-12-07 | 2019-06-13 | Bionomics Limited | Methods of treating agitation |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN114585362B (zh) | 2019-09-23 | 2024-05-07 | 生态有限公司 | 治疗制剂及其用途 |
| AU2023201463A1 (en) * | 2023-03-08 | 2024-09-26 | Bionomics Limited | Method of treating social anxiety disorder |
| WO2025033432A1 (ja) * | 2023-08-08 | 2025-02-13 | 株式会社明治 | 概日リズムの調整 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007502839A (ja) * | 2003-08-21 | 2007-02-15 | トランソラル ファーマシューティカルズ，インコーポレイティド | 口腔粘膜を介して５−ｈｔアゴニストを運搬するための組成物及びその使用方法 |
| JP5373613B2 (ja) | 2006-10-16 | 2013-12-18 | バイオノミクス リミテッド | 新規な抗不安薬化合物 |
| DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
| GB0706044D0 (en) * | 2007-03-28 | 2007-05-09 | Syngenta Ltd | C0-Crystals |
| BR112012013365A2 (pt) * | 2009-12-03 | 2016-03-01 | Astrazeneca Ab | co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais |
| EP2680842A4 (en) * | 2011-03-02 | 2014-10-29 | Bionomics Ltd | METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM |
| JP6055817B2 (ja) * | 2011-05-12 | 2016-12-27 | バイオノミックス リミテッド | ナフチリジンの調製方法 |
| AU2013204159B2 (en) * | 2013-03-15 | 2015-05-07 | Bionomics Limited | A Crystalline Form of an Anxiolytic Compound |
-
2014
- 2014-03-14 US US14/776,643 patent/US9745296B2/en active Active
- 2014-03-14 CN CN201480028564.4A patent/CN105492440A/zh active Pending
- 2014-03-14 EP EP14765186.3A patent/EP2970247A4/en not_active Withdrawn
- 2014-03-14 CA CA2905570A patent/CA2905570A1/en not_active Abandoned
- 2014-03-14 MX MX2015013059A patent/MX2015013059A/es unknown
- 2014-03-14 HK HK16108260.8A patent/HK1220191A1/zh unknown
- 2014-03-14 WO PCT/AU2014/000272 patent/WO2014138812A1/en not_active Ceased
- 2014-03-14 AU AU2014231722A patent/AU2014231722B2/en active Active
- 2014-03-14 JP JP2015561831A patent/JP2016510768A/ja active Pending
-
2017
- 2017-03-21 AU AU2017201916A patent/AU2017201916B2/en active Active
- 2017-08-25 US US15/687,274 patent/US10266529B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017201916B2 (en) | 2018-09-27 |
| WO2014138812A1 (en) | 2014-09-18 |
| AU2014231722A1 (en) | 2015-09-24 |
| CA2905570A1 (en) | 2014-09-18 |
| CN105492440A (zh) | 2016-04-13 |
| US9745296B2 (en) | 2017-08-29 |
| AU2014231722B2 (en) | 2016-12-22 |
| EP2970247A1 (en) | 2016-01-20 |
| US10266529B2 (en) | 2019-04-23 |
| HK1220191A1 (zh) | 2017-04-28 |
| US20160185770A1 (en) | 2016-06-30 |
| AU2017201916A1 (en) | 2017-04-13 |
| JP2016510768A (ja) | 2016-04-11 |
| EP2970247A4 (en) | 2016-08-10 |
| US20170362230A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013059A (es) | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| NZ713762A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| EA201400624A1 (ru) | Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1 | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| PH12017500920A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
| EP3438048A4 (en) | METHOD FOR PRODUCING BINAR-FREE, COAL-BASED, BRIKETTED ACTIVE CARBON | |
| NZ728707A (en) | 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides | |
| MX2016008898A (es) | Antagonistas selectivos de nr2b. | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
| MY192609A (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| SG10201810263QA (en) | Nampt inhibitors and methods | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| EA201791450A1 (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. |